LEE011
LEE011 is a pharmaceutical drug with 25 clinical trials. Currently 2 active trials ongoing. Historical success rate of 77.3%.
Success Metrics
Based on 17 completed trials
Phase Distribution
Phase Distribution
17
Early Stage
8
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
77.3%
17 of 22 finished
22.7%
5 ended early
2
trials recruiting
25
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Ribociclib (LEE011) Rollover Study for Continued Access
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Clinical Trials (25)
Ribociclib (LEE011) Rollover Study for Continued Access
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011
Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
A Phase I Study of LEE011 in Asian Patients
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 25